CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer, genitourinary cancers, multiple myeloma, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers and lung cancer.
  
  LEARNING OBJECTIVES

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, lung and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing clinical trials in breast, gastrointestinal, genitourinary, lung and select hematologic cancers, and refer appropriate patients for participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures in individualizing the care of patients with cancer.
  • Educate patients with hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer treatment algorithms, considering new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Neeraj Agarwal, MD
  Professor of Medicine
  Senior Director for Clinical Research Innovation
  Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
  Director, Center of Investigational Therapeutics
  Director, Genitourinary Oncology Program
  Huntsman Cancer Institute, University of Utah (NCI-CCC)
  Salt Lake City, Utah
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Janssen Biotech Inc, Lilly, Lumos Pharma, Medivation Inc, a Pfizer Company, Merck, Nektar, Novartis, Pfizer Inc, Prometheus Laboratories Inc, Rexahn Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc, Takeda Pharmaceuticals USA Inc, TRACON Pharmaceuticals Inc.
  
  Harold J Burstein, MD, PhD
  Institute Physician, Dana-Farber Cancer Institute
  Professor of Medicine, Harvard Medical School
  Boston, Massachusetts
  
  No relevant conflicts of interest to disclose.
  
  Ibiayi Dagogo-Jack, MD
  Assistant Professor of Medicine
  Harvard Medical School
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, BostonGene, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novocure Inc, Pfizer Inc, Sanofi Genzyme, Syros Pharmaceuticals Inc, Xcovery; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Genentech, a member of the Roche Group, Novartis, Pfizer Inc.
  
  Rafael Fonseca, MD
  Chief Innovation Officer
  Getz Family Professor of Cancer
  Distinguished Mayo Investigator
  Mayo Clinic in Arizona
  Phoenix, Arizona
  
  Consulting Agreements: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, H3 Biomedicine, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Merck, Novartis, Oncopeptides, ONCOtracker, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Scientific Advisory Board: Adaptive Biotechnologies Corporation, Caris Life Sciences, OncoMyx Therapeutics, ONCOtracker.
  
  Brad S Kahl, MD
  Professor of Medicine
  Washington University School of Medicine
  Director, Lymphoma Program
  Siteman Cancer Center
  St Louis, Missouri
  
  Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Celgene Corporation, MEI Pharma Inc, Takeda Pharmaceuticals USA Inc.
  
  Rutika Mehta, MD, MPH
  Assistant Member in the Department of Gastrointestinal Oncology
  Moffitt Cancer Center
  Assistant Professor in the Department of Oncologic Sciences
  University of South Florida
  Tampa, Florida
  
  Advisory Committee: Astellas, Bristol-Myers Squibb Company, Lilly; Consulting Agreement: Lilly; Speakers Bureau: Daiichi Sankyo Inc, Natera Inc.
  
  Craig Moskowitz, MD
  Physician in Chief and Interim Deputy Cancer Center Director
  Sylvester Comprehensive Cancer Center
  Professor of Medicine, Miller School of Medicine
  University of Miami Health System
  Miami, Florida
  
  Research Funding: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Incyte Corporation, Merck, Seagen Inc; Scientific Advisory Board: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Incyte Corporation, Merck, Molecular Templates, Seagen Inc, Takeda Pharmaceuticals USA Inc.
  
  Joyce O’Shaughnessy, MD
  Celebrating Women Chair in Breast Cancer Research
  Baylor University Medical Center
  Director, Breast Cancer Research Program
  Texas Oncology
  US Oncology
  Dallas, Texas
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Myriad Genetic Laboratories Inc, Nektar, Novartis, Ontada, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Syndax Pharmaceuticals Inc, Synthon, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Lilly, Pfizer Inc, Seagen Inc.
  
  Krina Patel, MD, MSc
  Associate Professor
  Department of Lymphoma/Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Arcellx, Bristol-Myers Squibb Company, Celgene Corporation, Cellectis, Curio Bioscience, Janssen Biotech Inc, Karyopharm Therapeutics, Legend Biotech, Merck, Pfizer Inc; Contracted Research: Allogene Therapeutics, Nektar.
  
  Philip A Philip, MD, PhD, FRCP
  Professor of Oncology and Pharmacology
  Leader, GI and Neuroendocrine Oncology
  Henry Ford Cancer Institute
  Wayne State University
  Detroit, Michigan
  
  No relevant conflicts of interest to disclose.
  
  Suresh S Ramalingam, MD
  Professor of Hematology and Medical Oncology
  Roberto C Goizueta Chair for Cancer Research
  Executive Director, Winship Cancer Institute
  Emory University School of Medicine
  Atlanta, Georgia
  
  Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Genmab, GlaxoSmithKline, Lilly, Merck, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Genmab, GlaxoSmithKline, Merck, Takeda Pharmaceuticals USA Inc; Contracted Research (to Institution): Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genmab, GlaxoSmithKline, Merck, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc.
  
  Sandy Srinivas, MD
  Professor of Oncology
  Clinical Research Leader, GU Oncology
  Stanford University
  Stanford, California
  
  Advisory Committee: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Novartis; Contracted Research: Bayer HealthCare Pharmaceuticals, Merck, Novartis; Data and Safety Monitoring Board/Committee: Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by an educational grant from AbbVie Inc, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Epizyme Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Lilly, Merck, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Puma Biotechnology Inc, Seagen Inc, and Taiho Oncology Inc.
  
  Release date: August 2022
  Expiration date: August 2023